Photo by Lukas on Pexels.com

Citibank to Pay More Than $38 Million for Improper Handling of ADRs

SEC Presss Release

Citibank to Pay More Than $38 Million for Improper Handling of ADRs

FOR IMMEDIATE RELEASE

2018-255

Washington D.C., Nov. 7, 2018 —
The Securities and Exchange Commission today announced that Citibank N.A. has agreed to pay $38.7 million to settle charges of improper handling of “pre-released” American Depositary Receipts (ADRs).

ADRs – U.S. securities that represent foreign shares of a foreign company – require a corresponding number of foreign shares to be held in custody at a depositary bank. The practice of “pre-release” allows ADRs to be issued without the deposit of foreign shares provided brokers receiving them have an agreement with a depositary bank and the broker or its customer owns the number of foreign shares that corresponds to the number of shares the ADR represents.

The SEC found that Citibank improperly provided ADRs to brokers in thousands of pre-release transactions when neither the broker nor its customers had the foreign shares needed to support those new ADRs. Such practices resulted in inflating the total number of a foreign issuer’s tradeable securities, which resulted in abusive practices like inappropriate short selling and dividend arbitrage that should not have been occurring.

This is the second action against a depositary bank and sixth action against a bank or broker resulting from the SEC’s ongoing investigation into abusive ADR pre-release practices. Information about ADRs is available in an SEC Investor Bulletin.

“Our charges against Citibank are the latest in our ongoing investigative effort to hold accountable Wall Street institutions that participated in an industry-wide fraud,” said Sanjay Wadhwa, Senior Associate Director of the SEC’s New York Regional Office. “Our investigation into these practices has revealed that banks and brokerage firms profited while ADR holders were unaware of how the market was being abused.”

Without admitting or denying the SEC’s findings, Citibank agreed to pay more than $20.9 million in disgorgement of ill-gotten gains plus $4.2 million in prejudgment interest and a $13.5 million penalty for a total of more than $38.7 million. The SEC’s order acknowledges Citibank’s remedial acts and cooperation in the investigation.

The SEC’s continuing industry-wide investigation is being conducted by Andrew Dean, Joseph P. Ceglio, William Martin, Elzbieta Wraga, Philip Fortino, Richard Hong, and Adam Grace of the New York Regional Office, and the case is being supervised by Mr. Wadhwa.

###
Source:

SEC.gov | Citibank to Pay More Than $38 Million for Improper Handling of ADRs

The SEC found that Citibank improperly provided ADRs to brokers in thousands of pre-release transactions when neither the broker nor its customers had the foreign shares needed to support those new ADRs. Such practices resulted in inflating the total number of a foreign issuer’s tradeable securities, which resulted in abusive practices like inappropriate short selling and dividend arbitrage that should not have been occurring.

Check Also

The Conference Board Economics Watch: Europe Brief – January 2019

Despite the moderate outlook, the unemployment rate in the Euro area has remained stable at 8.1 percent, since the summer of 2018. With unemployment reaching a decade low, companies feel the pain of talent shortages, especially in an aging labor market.

Brexit Uncertainty to Continue for at Least Another Two Months

A Statement from The Conference Board Press Release Provided By The Conference Board Jan 16, …

photos by pexels.com

Canopy Growth Receives New York State Hemp Licence and Will Establish U.S.-Based Commercial Operations

"Canopy Growth's $100-$150 million investment in the Southern Tier is a true win-win - for Canopy Growth, who will be positioned at the forefront of Upstate New York's industrial hemp revolution, and for the Southern Tier's economy and farmers, which will receive a major shot in the arm in new good-paying jobs. I fought so hard to strip the burdensome federal regulations from industrial hemp in our Industrial Hemp Farming Act of 2018, which was recently included in the Farm Bill, because I knew how much it could mean to the Southern Tier, and this investment proves it. I'm so pleased that Canopy Growth is joining my efforts to make the Southern Tier the Silicon Valley of industrial hemp production and research and will keep pushing to see industrial hemp become a true cash crop in the region," said Senator Schumer.

rawpixel.com photo

JPMorgan Chase Caught with Hands in Cookie Jar, Forced to Pay More Than $135 Million for Improper Handling of ADRs

The SEC’s order found that JPMorgan improperly provided ADRs to brokers in thousands of pre-release transactions when neither the broker nor its customers had the foreign shares needed to support those new ADRs. Such practices resulted in inflating the total number of a foreign issuer’s tradeable securities, which resulted in abusive practices like inappropriate short selling and dividend arbitrage that should not have been occurring.

Meridian Bioscience, Inc., Stock (VIVO) in Spot Light Today After FDA Granted Marketing Authorization of Alethia CMV Assay Test System to the Company

According to the Centers for Disease Control and Prevention, more than half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms of infection. However, CMV infection can cause serious health problems for people with weakened immune systems and for some newborns.

FDA Warns Consumers to Avoid Rhino Male Enhancement Products Found at Gas Station Retailers because of Undeclared and Potentially Dangerous Drug Ingredients

The FDA has received reports of people experiencing chest pain, severe headaches and prolonged erections after taking a Rhino product that led to surgical intervention and hospitalization due to extreme drops in blood pressure.

SEC Settles Insider Trading Claims Against Former Chairman and CEO of Advanced Medical Optics

The SEC's complaint alleged that in October 2008 Mazzo executed a nondisclosure agreement with Abbott Laboratories, Inc., as Abbott explored a potential acquisition of AMO...

%d bloggers like this: